
Vertex Pharmaceuticals (NASDAQ:VRTX) is preparing for a Nov. 30 U.S. regulatory decision on its kidney disease treatment povetacicept, while awaiting clinical results across kidney disease, chronic pain and other conditions, company executives said at a UBS investor event.
Susie Lisa, Vertex’s senior vice president of investor relations, said the company remains “fully on track” for the Food and Drug Administration’s decision on povetacicept for immunoglobulin A nephropathy, or IgAN. The company is ready to launch the treatment if it is approved, she said.
Lisa also reaffirmed Vertex’s expectation that JOURNAVX and CASGEVY, its products outside cystic fibrosis, will contribute more than $500 million toward the company’s annual revenue guidance of more than $13 billion. She said third-quarter cystic fibrosis growth was balanced between the U.S. and international markets.
Vertex Prepares for Kidney Drug Decision
Asked about investor concerns surrounding a contract manufacturer supporting povetacicept, Lisa did not discuss inspection or review specifics. She said the events expected during the FDA’s priority review had taken place and that Vertex had held positive interactions with the agency.
Lisa said povetacicept’s late-stage results included a greater than 50% reduction in proteinuria, or protein in the urine, at 36 weeks. She described the drug as a potential best-in-class treatment, while noting that there have been no head-to-head studies against competing products. The treatment is designed for monthly administration at home using an auto-injector.
Some investors have questioned whether reductions in immunoglobulin G, an antibody, could lead to safety concerns or additional monitoring requirements. Lisa said serious infection rates were 0.5% in both the povetacicept and placebo arms of the study. Vertex expects a label consistent with competing treatments, she said, while cautioning that monitoring differed across trials.
Two competing IgAN drugs have already launched, but Lisa said Vertex sees a substantial remaining opportunity. She estimated that 160,000 patients in the U.S. have a biopsy-confirmed IgAN diagnosis. More than 90% of Vertex’s trained renal sales force has prior nephrology experience, she said, and the company has held discussions with payers.
Inaxaplin Data and Genetic Testing
Vertex expects an interim analysis in the first quarter of 2027 from AMPLITUDE, a phase 3 study of inaxaplin for APOL1-mediated kidney disease, or AMKD. A positive result could put the drug on a path toward accelerated approval in the U.S., Lisa said.
The analysis will assess the slope of estimated glomerular filtration rate, a measure of kidney function, at 48 weeks. Lisa said earlier studies showed encouraging reductions in proteinuria, but distinguished that measure from the kidney-function endpoint being assessed for regulatory purposes.
Lisa estimated that the initial U.S. patient population could be about 150,000, rising to roughly 250,000 when patients with comorbidities such as type 2 diabetes are included. Most patients have not been diagnosed and would need genetic testing, she said. Vertex would likely launch inaxaplin with a companion diagnostic if the drug is approved.
Pain and Other Pipeline Updates
Results from two phase 3 studies of JOURNAVX in diabetic peripheral neuropathy are expected in the first half of 2027. Both compare the treatment with placebo, and one also includes pregabalin as a comparator. Lisa said managing the placebo effect is an important factor in the trials.
For acute pain, Lisa said Vertex is on track to more than triple JOURNAVX prescriptions in 2026 compared with 2025. Revenue conversion has been slower than some investors expected, however, partly because of reimbursement and prescription logistics. The company plans to keep its free-drug patient support program in place until the middle of 2027 before gradually phasing it out, she said.
Vertex also expects phase 2 proof-of-concept results in myotonic dystrophy type 1 before year-end. A separate pain program targeting NaV1.7 remains in late preclinical development, with the company hoping to enter clinical testing in 2027, Lisa said.
For atumelnant, a treatment being studied in congenital adrenal hyperplasia, Vertex expects to complete enrollment in its adult phase 3 study in the first quarter of 2027. Data disclosure is expected in late 2027 or early 2028, said Manisha Pai, executive director of investor relations.
Pai said Vertex has not set a timeline for data from an ongoing pediatric phase 2 study. In the adult phase 2 open-label extension, the company has not seen liver issues, she said; Vertex expects to share data from that extension at a medical meeting in 2027.
About Vertex Pharmaceuticals (NASDAQ:VRTX)
Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.
